TABLE OF CONTENTS
1 INTRODUCTION 41
1.1 OBJECTIVES OF THE STUDY 41
1.2 MARKET DEFINITION 41
1.3 OVERVIEW OF THE GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET 41
1.4 CURRENCY AND PRICING 43
1.5 LIMITATIONS 43
1.6 MARKETS COVERED 43
2 MARKET SEGMENTATION 46
2.1 MARKETS COVERED 46
2.2 GEOGRAPHICAL SCOPE 47
2.3 YEARS CONSIDERED FOR THE STUDY 48
2.4 DBMR TRIPOD DATA VALIDATION MODEL 49
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 52
2.6 MULTIVARIATE MODELLING 53
2.7 PRODUCT AND SERVICE SEGMENT LIFELINE CURVE 53
2.8 MARKET END USER COVERAGE GRID 54
2.9 DBMR MARKET POSITION GRID 55
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHTS 61
4.1 PESTEL ANALYSIS 64
4.2 PORTERS ANALYSIS 65
5 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, INDUSTRY INSIGHTS 66
6 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, REGULATIONS 68
7 MARKET OVERVIEW 71
7.1 DRIVERS 73
7.1.1 INCREASING DEMAND FOR TOXICOLOGY TESTING PRODUCTS 73
7.1.2 RAPIDLY GROWING PHARMACEUTICAL AND MEDICAL DEVICE INDUSTRIES 73
7.1.3 RISING INVESTMENT IN R&D BY KEY MARKET PLAYERS 74
7.1.4 TECHNOLOGICAL ADVANCEMENTS TO DEVELOP NEW TOXICOLOGY TESTING METHODS 74
7.2 RESTRAINTS 75
7.2.1 HIGH COSTS ASSOCIATED WITH IN-VITRO TOXICOLOGY TESTING AND PRODUCTS 75
7.2.2 COMPLEXITY OF BIOLOGICAL SYSTEMS 75
7.2.3 NEED FOR SKILLED PERSONNEL AND INFRASTRUCTURE 76
7.3 OPPORTUNITIES 76
7.3.1 GROWING ADOPTION OF QUALITY CHECK PRODUCTS TO PREVENT PRODUCT RECALLS 76
7.3.2 STRATEGIC INITIATIVES BY KEY MARKET PLAYERS FOR MARKET EXPANSION 77
7.3.3 GROWING DEMAND FOR PERSONALIZED MEDICINE AND PRECISION TOXICOLOGY 77
7.4 CHALLENGES 78
7.4.1 ETHICAL AND PUBLIC PERCEPTION 78
7.4.2 REGULATORY ACCEPTANCE AND ENDORSEMENT OF IN-VITRO TESTING METHODS 78
8 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY PRODUCT AND SERVICE 79
8.1 OVERVIEW 80
8.2 CONSUMABLES 83
8.3 SERVICES 84
8.3.1 CYTOTOXICITY 85
8.3.2 GENE TOXICITY 85
8.3.3 HEPATOTOXICITY 85
8.3.4 OPHTHALMIC TOXICITY 85
8.3.5 CARDIOTOXICITY 85
8.3.6 NEPHROTOXICITY 85
8.3.7 NEUROTOXICITY 86
8.3.8 OTHERS 86
8.4 ASSAYS 86
8.4.1 CELL-BASED ELISA & WESTERN BLOTS 87
8.4.2 ENZYME TOXICITY ASSAYS 87
8.4.3 RECEPTOR-BINDING ASSAYS 87
8.4.4 BACTERIAL TOXICITY ASSAYS 87
8.4.5 TISSUE CULTURE ASSAYS 87
8.4.6 OTHER ASSAYS 87
8.5 EQUIPMENTS 88
8.6 SOFTWARE 89
9 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY TOXICOLOGY ENDPOINT AND TEST 90
9.1 OVERVIEW 91
9.2 ADME (ABSORPTION, DISTRIBUTION, METABOLISM, & EXCRETION) TESTING 94
9.3 CYTOTOXICITY TESTING 95
9.4 GENOTOXICITY TESTING 96
9.5 DERMAL TOXICITY TESTING 97
9.6 OCULAR TOXICITY TESTING 98
9.7 ORGAN TOXICITY TESTING 99
9.8 SKIN IRRITATION, CORROSION, & SENSITIZATION TESTING 100
9.9 PHOTOTOXICITY TESTING 100
9.10 OTHER TOXICITY ENDPOINTS AND TESTS 101
10 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY TECHNOLOGY 103
10.1 OVERVIEW 104
10.2 CELL CULTURE TECHNOLOGIES 107
10.3 HIGH-THROUGHPUT TECHNOLOGIES 108
10.4 MOLECULAR IMAGING 109
10.5 OMICS TECHNOLOGY 110
11 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY METHOD 111
11.1 OVERVIEW 112
11.2 CELLULAR ASSAYS 114
11.3 BIOCHEMICAL ASSAYS 115
11.4 EX-VIVO MODELS 116
11.5 IN SILICO MODELS 117
12 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY INDUSTRY 119
12.1 OVERVIEW 120
12.2 PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES 123
12.2.1 CONSUMABLES 124
12.2.2 SERVICES 124
12.2.3 ASSAYS 124
12.2.4 EQUIPMENTS 124
12.2.5 SOFTWARE 124
12.3 DIAGNOSTICS 124
12.3.1 CONSUMABLES 126
12.3.2 SERVICES 126
12.3.3 ASSAYS 126
12.3.4 EQUIPMENTS 126
12.3.5 SOFTWARE 126
12.4 FOOD 126
12.4.1 CONSUMABLES 127
12.4.2 SERVICE 127
12.4.3 ASSAYS 127
12.4.4 EQUIPMENTS 128
12.4.5 SOFTWARE 128
12.5 CHEMICALS 128
12.5.1 CONSUMABLES 129
12.5.2 SERVICES 129
12.5.3 ASSAYS 129
12.5.4 EQUIPMENTS 129
12.5.5 SOFTWARE 129
12.6 COSMETICS AND HOUSEHOLD PRODUCTS 130
12.6.1 CONSUMABLES 131
12.6.2 SERVICES 131
12.6.3 ASSAYS 131
12.6.4 EQUIPMENTS 131
12.6.5 SOFTWARE 131
13 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY DISTRIBUTION CHANNEL 132
13.1 OVERVIEW 133
13.2 DIRECT TENDER 135
13.3 RETAIL SALES 136
13.4 OTHERS 137
14 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, BY REGION 139
14.1 OVERVIEW 140
14.2 NORTH AMERICA 145
14.2.1 U.S. 154
14.2.2 CANADA 159
14.2.3 MEXICO 164
14.3 EUROPE 169
14.3.1 GERMANY 178
14.3.2 U.K. 183
14.3.3 FRANCE 188
14.3.4 ITALY 193
14.3.5 RUSSIA 198
14.3.6 SPAIN 203
14.3.7 NETHERLANDS 208
14.3.8 2.8 SWITZERLAND 213
14.3.9 BELGIUM 218
14.3.10 TURKEY 223
14.3.11 REST OF EUROPE 228
14.4 ASIA PACIFIC 229
14.4.1 CHINA 238
14.4.2 JAPAN 243
14.4.3 INDIA 248
14.4.4 AUSTRALIA 253
14.4.5 SOUTH KOREA 258
14.4.6 INDONESIA 263
14.4.7 PHILIPPINES 268
14.4.8 THAILAND 273
14.4.9 MALAYSIA 278
14.4.10 SINGAPORE 283
14.4.11 REST OF ASIA-PACIFIC 288
14.5 SOUTH AMERICA 289
14.5.1 BRAZIL 298
14.5.2 ARGENTINA 303
14.5.3 REST OF SOUTH AMERICA 308
14.6 MIDDLE EAST AND AFRICA 309
14.6.1 SAUDI ARABIA 318
14.6.2 SOUTH AFRICA 323
14.6.3 U.A.E. 328
14.6.4 EGYPT 333
14.6.5 ISRAEL 338
14.6.6 REST OF MIDDLE EAST AND AFRICA 343
15 GLOBAL IN-VITRO TOXICOLOGY TESTING MARKET, COMPANY LANDSCAPE 344
15.1 COMPANY SHARE ANALYSIS: GLOBAL 344
15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 345
15.3 COMPANY SHARE ANALYSIS: EUROPE 346
15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 347
16 SWOT ANALYSIS 348
17 COMPANY PROFILE 349
17.1 THERMO FISHER SCIENTIFIC INC. 349
17.1.1 COMPANY SNAPSHOT 349
17.1.2 REVENUE ANALYSIS 349
17.1.3 COMPANY SHARE ANALYSIS 350
17.1.4 PRODUCT PORTFOLIO 350
17.1.5 RECENT DEVELOPMENT 350
17.2 LABCORP DRUG DEVELOPMENT 351
17.2.1 COMPANY SNAPSHOT 351
17.2.2 REVENUE ANALYSIS 351
17.2.3 COMPANY SHARE ANALYSIS 352
17.2.4 PRODUCT PORTFOLIO 352
17.2.5 RECENT DEVELOPMENT 352
17.3 MERCK KGAA 353
17.3.1 COMPANY SNAPSHOT 353
17.3.2 REVENUE ANALYSIS 353
17.3.3 COMPANY SHARE ANALYSIS 354
17.3.4 PRODUCT PORTFOLIO 354
17.3.5 RECENT DEVELOPMENT 354
17.4 CHARLES RIVER LABORATORIES. 355
17.4.1 COMPANY SNAPSHOT 355
17.4.2 REVENUE ANALYSIS 355
17.4.3 COMPANY SHARE ANALYSIS 356
17.4.4 PRODUCT PORTFOLIO 356
17.4.5 RECENT DEVELOPMENT 356
17.5 LONZA 357
17.5.1 COMPANY SNAPSHOT 357
17.5.2 REVENUE ANALYSIS 357
17.5.3 COMPANY SHARE ANALYSIS 358
17.5.4 PRODUCT PORTFOLIO 358
17.5.5 RECENT DEVELOPMENT 358
17.6 AAT BIOQUEST, INC. 359
17.6.1 COMPANY SNAPSHOT 359
17.6.2 PRODUCT PORTFOLIO 359
17.6.3 RECENT DEVELOPMENTS 359
17.7 ARAGEN LIFE SCIENCES LTD. 360
17.7.1 COMPANY SNAPSHOT 360
17.7.2 REVENUE ANALYSIS 360
17.7.3 PRODUCT PORTFOLIO 361
17.7.4 RECENT DEVELOPMENT 361
17.8 BIOIVT 362
17.8.1 COMPANY SNAPSHOT 362
17.8.2 PRODUCT PORTFOLIO 362
17.8.3 RECENT DEVELOPMENT 362
17.9 BIO-RAD LABORATORIES, INC. 363
17.9.1 COMPANY SNAPSHOT 363
17.9.2 REVENUE ANALYSIS 363
17.9.3 PRODUCT PORTFOLIO 364
17.9.4 RECENT DEVELOPMENT 364
17.10 CATALENT, INC 365
17.10.1 COMPANY SNAPSHOT 365
17.10.2 REVENUE ANALYSIS 365
17.10.3 PRODUCT PORTFOLIO 366
17.10.4 RECENT DEVELOPMENT 366
17.11 CREATIVE BIOARRAY. 367
17.11.1 COMPANY SNAPSHOT 367
17.11.2 PRODUCT PORTFOLIO 367
17.11.3 RECENT DEVELOPMENTS 367
17.12 CREATIVE BIOLABS. 368
17.12.1 COMPANY SNAPSHOT 368
17.12.2 PRODUCT PORTFOLIO 368
17.12.3 RECENT DEVELOPMENTS 368
17.13 CYPROTEX LIMITED 369
17.13.1 COMPANY SNAPSHOT 369
17.13.2 PRODUCT PORTFOLIO 369
17.13.3 RECENT DEVELOPMENT 369
17.14 EUROFINS SCIENTIFIC 370
17.14.1 COMPANY SNAPSHOT 370
17.14.2 REVENUE ANALYSIS 370
17.14.3 PRODUCT PORTFOLIO 371
17.14.4 RECENT DEVELOPMENT 371
17.15 GENTRONIX 372
17.15.1 COMPANY SNAPSHOT 372
17.15.2 PRODUCT PORTFOLIO 372
17.15.3 RECENT DEVELOPMENT 372
17.16 IONTOX 373
17.16.1 COMPANY SNAPSHOT 373
17.16.2 PRODUCT PORTFOLIO 373
17.16.3 RECENT DEVELOPMENT 373

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.